TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 1 to \<5 years on the day of inclusion~* History of received 1 dose of CD.JEVAX at 9-15 months prior to enrollment~* In good general health at the time of inclusion~* Provision of informed consent by the parent(s) or legal guardian(s)~Exclusion Criteria:~* Receipt of blood or blood products in the past 3 months~* Acute febrile illness on the day of vaccination (Body Temperature ≥ 38 ◦C)~* Previous receipt of 2 doses of any vaccine against JE virus~* Known hypersensitivity to any of the vaccine components~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* Planned receipt of any live attenuated vaccine within 4 weeks following the trial vaccination

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Imojev (Type: EXPERIMENTAL): Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is between the ages of 18 and 80.~2. Major depressive disorder or depressive disorder not otherwise specified as ascertained by a physician or mental health professional licensed to diagnose.~3. Patient is an outpatient and not in imminent need of inpatient hospitalization, or a discharging inpatient with scheduled follow-up with a Behavioral Health psychiatrist.~4. Patient has been referred to see a psychiatrist for optimum medication management.~5. Patient's Hamilton Depression Rating score is \>14~6. Ability to read, understand and sign an informed consent document~Exclusion Criteria:~1. Serious medical illness (as ascertained via the initial triage screening process)~2. Patients with a diagnosis of Bipolar I disorder~3. Patients with a diagnosis of Schizophrenia or Schizoaffective disorder~4. Patients who are legally unable to consent to enrollment in the study (i.e. patients with legal guardians)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Guided (Type: EXPERIMENTAL): A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
- Unguided (Type: NO_INTERVENTION): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Referring for upper GI endoscopy~* Age 18 to 65 years~* First experience of upper GI endoscopy~* Class I or II of American Anesthesiology Association~* Willingness to participate~Exclusion Criteria:~* Severe psychiatric, neurological, cardio-vascular, or renal disorders~* History of allergy or intolerance to benzodiazepines or lidocaine~* History of upper GI surgery~* Pregnancy or lactation~* GI anomalia during endoscopy~* Need for therapeutic procedures during endoscopy~* Active bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Oral placebo (Type: PLACEBO_COMPARATOR): Patients receive one oral dose of placebo least 30 minutes before the procedure.
- Sublingual placebo (Type: PLACEBO_COMPARATOR): Patients receive one oral dose of placebo at least 30 minutes before the procedure.
- Sublingual alprazolam (Type: ACTIVE_COMPARATOR): Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
- Oral alprazolam (Type: ACTIVE_COMPARATOR): Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction.~Exclusion Criteria:~1. Other etiologies of fluid overload different from heart failure.~2. Hyponatremia: Sodium level below 125mmol/l~3. Unstable patients: acute coronary syndrome, cardiogenic shock .~4. Patients requiring inotropic agents or renal dialysis.~5. Pregnancy or breastfeeding period.~6. sever hepatic disease~7. GFR is less than 45 mL/min/1.73 m² .~8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin group (Type: ACTIVE_COMPARATOR): 50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
- Placebo group (Type: PLACEBO_COMPARATOR): 50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive blood culture with Gram stain showing GNB identified during local laboratory business hours.~Exclusion Criteria:~* Identification of GNB outside of local laboratory business hours (e.g. whenever laboratories are staffed to perform both rapid testing and routine testing)~* Positive blood culture for GNB at the same institution within prior 7 days (if known at the time of randomization).~* Deceased at the time of randomization.~* GNB plus gram-positive organism, gram-negative cocci, and/or yeast detected on Gram stain~* Previous enrollment in this study~* No Minnesota research authorization (Rochester site only)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard blood culture and AST (Type: ACTIVE_COMPARATOR): Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
- Rapid organism identification and AST (Type: ACTIVE_COMPARATOR): Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have presumed malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of stereotactic biopsy or resection prior to NSC-CRAd-S-pk7 injection; if this is not possible, the injection will not be performed and the subject will no longer be eligible for the study).~* Tumor must be accessible for injection and must not be located in the brainstem, or contained within the ventricular system.~* Planning to undergo standard radiation/chemotherapy~* 18 years of age or older.~* Performance status must be KPS ≥ 70~* SGOT (AST) \< 3x upper limit of normal~* Serum creatinine \< 2mg/dl~* Platelets \> 100,000/mm3 and WBC \> 3000/mm3~Exclusion Criteria:~* Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection.~* Immunosuppressive drugs (with exception of corticosteroid).~* Known HIV+ patients.~* Acute infections (viral, bacterial or fungal infections requiring therapy).~* Pregnant or breast-feeding patients.~* Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).~* Prior radiation therapy to the brain or prior treatment for brain tumor Other serious co-morbid illness or compromised organ function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unresectable disease (Type: EXPERIMENTAL): Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
- Resectable disease (Type: EXPERIMENTAL): Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed (e.g. more than 6 months ago) primary adrenal insufficiency with a stable daily glucocorticoid substitution dose for at least 3 months prior to study entry~* Signed informed consent to participate in the study.~Exclusion Criteria:~* Clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, Hepatobiliary, pancreatic disease~* Clinically significant renal dysfunction~* Clinical or laboratory signs of significant gastrointestinal emptying or motility disease~* Any medication with agents which could interfere with hydrocortisone kinetics~* Pregnant or lactating women~* Regular dehydroepiandrosterone (DHEA) medication for the past 4 weeks~* Oral oestrogen medication for the past 4 weeks~* Deranged mineralocorticoid status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Novel once daily modified release (Type: EXPERIMENTAL): Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state
- Conventional TID hydrocortisone (Type: ACTIVE_COMPARATOR): Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, \>=18 years of age;~* locally advanced, inflammatory or early stage invasive breast cancer;~* HER2 positive (HER2+++ by IHC or FISH/CISH+).~Exclusion Criteria:~* metastatic disease (Stage IV) or bilateral breast cancer;~* previous anticancer therapy or radiotherapy for any malignancy;~* other malignancy, other than cancer in situ of the cervix, or basal cell cancer;~* insulin-dependent diabetes;~* clinically relevant cardiovascular disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Subject is a female of at least 18 years of age~2. Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)~Key Exclusion Criteria:~1. Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)~2. Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization~3. Subject is actively menstruating at the time of the Baseline visit.~4. Subject has uncontrolled diabetes mellitus.~5. Subject has a vaginal sample with pH \>4.5.~6. Subject has a history of or an active cervical/vaginal cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluconazole (Type: ACTIVE_COMPARATOR): 150 mg/day for 1 day
- Ibrexafungerp 750mg (Type: EXPERIMENTAL): 750mg QD for 1 day only
- Ibrexafungerp 300mg (Type: EXPERIMENTAL): 300mg BID for 1 day only
- Ibrexafungerp 450mg (Type: EXPERIMENTAL): 450mg BID for 1 day only
- Ibrexafungerp 150mg (Type: EXPERIMENTAL): 150mg BID for 3 days
- Ibrexafungerp 300mg D1-D3 (Type: EXPERIMENTAL): 300mg BID for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Natriuretic Effect of GLP-1in Healthy Non Obese Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria:~* Participant is ≥18 and ≤70 years of age on day of signing informed consent~* Participant is a male, or a female who is unlikely to conceive, as indicated by at least one yes answer to the following questions:~  * Patient is a surgically sterilized female~ * Patient is a postmenopausal female ≥45 years of age with \>2 years since last menses~ * Patient is a non-sterilized, premenopausal female and agrees to abstain from heterosexual activity or to use an adequate method of contraception ( Note: Acceptable methods of birth control are: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy)~* BMI ≥185 and ≤25~* Healthy as determined by:~  * Complete medical history, physical exam and~ * Standard 12-lead EKG~ * Complete blood count, blood chemistry , urinalysis with microscopy~ * Kidney USG~* Participant understands the study procedures, and risks involved with the study and voluntarily agree to participate by giving informed written consent.~Exclusion Criteria:• History of hypertension, diabetes (ADA guidelines), kidney disease~o Participant has impaired renal function defined as glomerular filtration lower than 90 calculated by Cockcroft-Gault formula and 24 creatinine, also by urinary protein excretion \> 200 mg/day or continuing active urinary sediment~* History of myocardial infarction, cerebrovascular accident or transient ischemic attack~* History of malignancy within last 5 years~* Current febrile state~* Participant is pregnant or nursing woman~* Failure to give informed consent or comply with the protocol~* Participant has received treatment with an investigational drug within the prior 3 months or is otherwise participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Saline infusion (Type: ACTIVE_COMPARATOR): infusion of saline
- Saline infusion with GLP1 (Type: ACTIVE_COMPARATOR): infusion of saline with GLP1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or non-pregnant, non-lactating female patients at least 18 years of age~* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)~* Rheumatoid factor and anti-CCP antibodies negative~* Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cm diameter or nail changes consistent with psoriasis or documented history o plaque psoriasis~Exclusion criteria:~* Chest X-ray with evidence of ongoing infectious or malignant process~* Subjects who have previously been treated with more than 3 different TNFα inhibitors~* Subjects taking high potency opioid analgesics~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Secukinumab (75mg)
- Group 2 (Type: EXPERIMENTAL): Secukinumab (150 mg)
- Group 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wearable Sensors in Knee OA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 50 years of age~* A confirmed clinical diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria (confirmed by the participant's physician).~* Score ≥ 3 on weight-bearing questions from the Knee injury and Osteoarthritis Outcome Score (KOOS) Pain Subscale in the index knee~* BMI ≤ 40 kg/m2~* Able to walk without assisted devices (eg. cane or walker) for at least 20 minutes~* Can speak and understand English~* Available for the study duration~Exclusion Criteria:~* Contraindication to exercise~* Other pain in lower back or legs that is greater than knee pain~* Currently receiving chemotherapy or radiation therapy for cancer except non-melanoma skin cancer~* History of other disease that may involve the index joint including inflammatory joint disease such as rheumatoid arthritis, seronegative spondyloarthropathy (eg, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease related arthropathy), crystalline disease (eg, gout or pseudogout), lupus erythematosus, knee joint infections, Paget's disease affecting the knee, or knee joint tumors.~* Any knee surgery in the previous 6 months~* Previous knee osteotomy, uni-compartmental replacement, or total knee replacement in either knee~* Joint replacement in either hip or ankle~* Planned major treatment for knee OA (e.g., surgery, injections, physical therapy) during the study period~* Planned major surgery in the next 6 months~* Corticosteroid or hyaluronic acid injections in either knee in the previous 3 months~* Neurological conditions that impacts motor functioning, for e.g., stroke, Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, diabetic neuropathy, etc.~* Pregnant~* Received physical therapy for knee OA within past 6 months~* Known or suspected non-compliance, drug or alcohol abuse~* Participation in another clinical trial for treatment of any joint or muscle pain~* Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigators.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise-based Physical Therapy (Type: EXPERIMENTAL): 12 week in-person exercise-based physical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete